131I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment.
The aim of this study is to evaluate the safety and long-term results of (131)I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment. From January 2002 to December 2012, 408 patients with refractory severe hyperthyroidism were treated with (131)I alone. Among them, 345 were followed up for 1 to 10 years for physical examination, thyroid function, and thyroid ultrasound. Complete Blood Count (CBC) liver function, electrocardiogram, echocardiogram, and Emission Computed Tomography (ECT) thyroid imaging were performed as indicated. The 345 patients had concomitant conditions including thyrotoxic heart disease, severe liver dysfunction, enlarged thyroid weighing 80 to 400 g, severe cytopenia, and vasculitis. One to two weeks prior to (131)I therapy, all patients were given low-iodine diet. The dose of (131)I therapy was 2.59 to 6.66 MBq (70 to180 µCi) per gram of thyroid with an average of 3.83 ± 0.6 MBq (103.6 ± 16.4 µCi); and the total (131)I activity administrated for the individuals was 111 to 3507.6 MBq (3.0 to 94.8 mCi, mean 444 ± 336.7 MBq (12.0 ± 9.1 mCi)). Out of the 408 patients, 283 were cured, 15 with complete remission, and 47 with incomplete remission. No treatment failure or significant clinical worsening was noted in these patients. Our data indicated that (131)I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment is safe and effective.
Department of Nuclear Medicine, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China dingyong307h@163.com.
Yong
Y
Ding
Department of Nuclear Medicine, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Jialiu
J
Xing
Department of Endocrinology, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Yi
Y
Fang
Department of Nuclear Medicine, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Yong
Y
Wang
Department of Nuclear Medicine, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Youren
Y
Zhang
Department of Nuclear Medicine, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China.
Yahong
Y
Long
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D013956:Antithyroid Agents / Q000008:administration & dosage*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006980:Hyperthyroidism / Q000532:radiotherapy*; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D013961:Thyroid Gland / Q000000981:diagnostic imaging / Q000473:pathology / Q000502:physiology; D016896:Treatment Outcome; D014463:Ultrasonography; D055815:Young Adult
D013956:Antithyroid Agents; D007457:Iodine Radioisotopes
Radioactive iodine; refractory severe hyperthyroidism; without antithyroid drug pretreatment